Treatment of multiple myeloma (MM), a neoplasm of plasma cells, formerly dependent on alkylating drugs, corticosteroids, and autologous stem cell transplantation, has changed dramatically in the past 20 years because 3 new classes of small molecule drugs (arbitrarily defined as having a molecular weight of < 900 kDa)-immunomodulators, proteasome inhibitors, and histone deacetylase blockers-have been introduced for the disease. Therapeutic options for MM expanded further in 2015 when 2 new monoclonal antibodies (daratumumab and elotuzumab) were approved by the Food and Drug Administration for MM. Although MM remains incurable, the cumulative effect of these advances has resulted in a near-doubling of the 5-year survival rate since the late 1980s. Despite these advances, therapy for MM continues to pose substantial challenges because resistance to therapy frequently develops, and relapse and recurrence are all too common. The present review focused on the pipeline for new small molecules in various stages of development and their associated cellular targets. In addition to newer versions of alkylators, immunomodulators, proteasome inhibitors, and histone deacetylase inhibitors, the present review considered the prospects for adding new classes of small molecules to the MM armamentarium, which offer the potential for oral efficacy, relative simplicity of preparation, and prospects for improvement in the cost-to-benefit ratio. Included are agents that affect myeloma epigenetics and the ubiquitinationeproteasome system and the unfolded protein response, apoptotic mechanisms, chromosomal abnormalities, nuclear protein transport, and various kinases involved in cellular signaling pathways.
Introduction
Ranking behind lymphomas and leukemias, multiple myeloma (MM), a neoplastic disorder of the plasma cells, is the third most common blood cancer, with an estimated 30,770 (46.7% female; 53.3% male) newly diagnosed cases annually in the United States. 1 For several decades, the standard therapy for MM included a combination of alkylating agents, primarily melphalan and cyclophosphamide, together with corticosteroids, such as dexamethasone and prednisone, all of which were augmented in the mid-1980s by the introduction of autologous stem cell transplantation. The past 2 decades, beginning with the discovery of thalidomide's beneficial immunomodulatory effects in the late 1990s, have seen a radical shift in the therapeutic measures available to treat MM. Thalidomide was followed by the introduction of the additional immunomodulators (IMiDs) lenalidomide and pomalidomide, proteasome inhibitors bortezomib, carfilzomib, and ixazomib, and the histone deacetylase (HDAC) inhibitor panobinostat. Added to these advances was the approval in late 2015 of 2 monoclonal antibodies, daratumumab and elotuzumab, directed against the CD38 and SLAMF7 antigens, respectively, found on the surface of myeloma cells. In the aggregate, these advances have resulted in a near doubling of the MM 5-year survival rate to w50% during the past 30 years. 1 The most current recommendations concerning the Despite the successes realized in the treatment of MM during the past 20 years, the search for a cure has remained elusive. On the positive side, these therapeutic advances have changed the disease's consequences in many cases from one with a rapidly fatal outcome to one more resembling a chronic condition, an optimism often tempered by disease recurrence and relapse because resistance is commonly observed after successful induction of therapeutic measures. Thus, the search for effective treatment regimens for MM continues unabated, with a trend toward immunologic approaches, including novel highly targeted monoclonal antibodies and chimeric antigen receptor T-cell therapy. In addition, research into "small molecules" (ie, those with molecular weights of < 900 kDa) to treat MM proceeds undiminished, because, in contrast to immune-based therapies, small molecules offer the potential for oral effectiveness and relative simplicity of synthetic preparation, in addition to the prospect for realizing favorable cost-to-benefit ratios. 3 Although designing small molecules to interfere with the interactions involving far larger biomolecules, such as protein domains or DNA sequences, poses substantial problems from the computer-assisted drug design standpoint, the field of medicinal chemistry is replete with numerous success stories, for example, the introduction of orally effective tyrosine kinase inhibitors into oncology practice. The present review is intended to provide a comprehensive overview of the current state of the pipeline leading to the introduction of new small molecules for the treatment of MM. Highlighted are all the new chemical entities classed as small molecules, currently lacking Food and Drug Administration (FDA) approval for MM, that have either entered into clinical trials for MM or, in some cases, have shown significant potential to do so from the results of preclinical studies. The compounds noted in the present review were selected from information contained in 2321 myelomabased trials in the ClinicalTrials.gov database that were initiated from November 1, 1999 to May 31, 2018 and a review of the pertinent reported data contained in the PubMed database. The discussion that follows was divided on the basis of the putative molecular and/or cellular targets for each compound or groups.
Alkylating Agents
The activity of melphalan (Alkeran, sarcolysin, L-phenylalanine mustard), a DNA-alkylating nitrogen mustard derivative, in MM patients was first reported in 1958. 4 This alkylating agent, along with other drugs in this class, often combined with corticosteroids, remained the standard therapy for MM for > 40 years until the introduction of bortezomib and the immunomodulators thalidomide and lenalidomide early in the 21st century. Recently, interest has been renewed in the discovery of new alkylating agents for MM treatment. Most of this attention has focused on bendamustine, a molecular hybrid consisting of a purine analog linked to a reactive mustard functionality and currently approved by the FDA for chronic lymphocytic leukemia (CLL) and indolent B-cell nonHodgkin lymphoma. Furthermore, this agent has been licensed in Europe for MM, based on a phase III study of 131 patients with recently diagnosed MM, in whom a combination of bendamustine and prednisone proved superior to melphalan and prednisolone in terms of the percentage of complete remissions, duration of remission, and time to treatment failure. 5 A more recently reported study of bendamustine, prednisone, and bortezomib found an 82% objective response rate (ORR) in 49 patients with recently diagnosed myeloma. 6 The National Cancer Institute's ClinicalTrials.gov website (accessed May 31, 2018) listed 34 studies involving bendamustine in various combinations for myeloma patients (a selected list of trials is provided in Table 1 ), although none of these investigations has progressed beyond phase II. Tinostamustine (EDO-S101), a fusion molecule that combines the molecular features of bendamustine and the HDAC inhibitor vorinostat, was reported to display good activity in preclinical studies of myeloma patient cells. 7 This agent now is in a phase I trial (ClinicalTrials.gov identifier, NCT02576496) of patients with lymphoma and myeloma previously shown to be refractory to treatment (Table 1) . Melflufen or melphalan-flufenamide, the amide of melphalan with p-fluorophenylalanine ethyl ester, was designed to take advantage of overexpression of aminopeptidase N, which in tumor cells cleaves melphalan from the conjugate, leading to higher intracellular concentrations of the parent DNA alkylator compared with melphalan alone. Preclinical work demonstrated melflufen's capacity to induce irreversible DNA damage and apoptosis in myeloma cells, in particular, those resistant to melphalan. 8 A phase II study of melflufen and dexamethasone in 34 evaluable relapsed and/or refractory MM (RRMM) patients (ClinicalTrials.gov identifier, NCT01897714) showed an ORR of 41% and a clinical benefit rate of 62%. Although hematologic toxicity was common, nonhematologic adverse events were infrequently reported. 9 Patient recruitment for a phase III study, the OCEAN (a study of melflufen-dex or pomalidomide-dex for RRMM patients refractory to lenalidomide; ClinicalTrials.gov identifier, NCT03151811) trial, comparing pomalidomide plus dexamethasone with melflufen plus dexamethasone in lenalidomide-refractory myeloma patients is in progress (Table 1) . Evofosfamide (TH-302) is an alkylating agent that works by a different mechanism than that of melphalan. This hypoxia-activated nitroimidazole prodrug of bromoisophosphoramide has been shown to induce apoptosis in synergy with bortezomib in myeloma cells both in vitro and in vivo. A reported phase I clinical study (ClinicalTrials.gov identifier, NCT01522872; Table 1 ) of evofosfamide in RRMM patients pretreated with bortezomib and lenalidomide showed a 42% clinical response rate, with myositis being the major adverse event.
10 PT-112, a platinum-based compound under development, is the subject of 3 clinical trials, including a phase I/II dose-determining study (ClinicalTrials.gov identifier, NCT03288480; Table 1 ) in RRMM patients.
Immunomodulating Agents
The use of IMiDs in the treatment of MM stems from the revival of thalidomide in the 1990s from its ignominious teratogenic past when it was not only approved by the FDA for treatment of leprosy, but also demonstrated "marked and durable responses" in a phase II study of 84 RRMM patients, 11 16 referred to as "a first in-class pleiotropic pathway modifier," recruiting for a phase I study of patients with advanced solid tumors, non-Hodgkin lymphoma, and MM (ClinicalTrials.gov identifier, NCT01421524); CC-220, 17 the subject of an ongoing phase I study with dexamethasone in RRMM (ClinicalTrials.gov identifier, NCT02773030); and CC-92480, the focus of a similar trial initiated in late 2017 (ClinicalTrials.gov identifier, NCT03374085).
UbiquitineProteasome System
Most proteins that participate in processes critical for normal cellular functioning eventually are degraded through the ubiquitinationeproteasome pathway, whose role in MM has been the subject of a recent extensive review. 18 The first step in the Much of the interest in proteasome inhibitors as antitumor agents arises from the observed greater sensitivity of malignant cells to proteasome inhibition compared with normal cells, a consequence that has been ascribed to proteotoxic stress induction and triggering of apoptosis through activation of the unfolded protein response (UPR). 19 In 2003, bortezomib (Velcade; PS-341), a boronic acid dipeptide derivative, became the first marketed proteasome inhibitor when it received accelerated FDA approval for the treatment of RRMM after previous therapy. Subsequently, in 2008, bortezomib was approved for initial treatment of MM and later, in 2014, for retreatment of patients whose myeloma had previously responded to bortezomib and had experienced a relapse ! 6 months after completion of that therapy and for front-line treatment of mantle cell lymphoma (MCL). 20 Bortezomib primarily acts by reversible inhibition of the chymotrypsin-like (CT-L) activity of the proteasome beta-5 subunit. Various hypotheses have been advanced to explain the potent antimyeloma activity of bortezomib. One theory derives from reports that the NF-kB pathway is constitutively elevated in MM and is a major factor driving the proliferation and survival of myeloma cells by promoting antiapoptotic signaling through regulation of IL-6 and insulin-like growth factor-1 expression and the induction of angiogenesis. According to this premise, blockage of the proteolysis of NF-kB inhibitor I-kB prevents NF-kB from binding to promoters of target genes such as antiapoptotic genes and IL-6 and other signaling molecules involved in this pathway to tip the balance to favor apoptosis. 21 Given intravenously, bortezomib has been the subject of numerous trials in various combinations, primarily with IMiDs and/or conventional chemotherapeutic drugs (eg, melphalan, cyclophosphamide, and doxorubicin), and often including glucocorticoids (dexamethasone or prednisone). 22 Peripheral neuropathy, a significant adverse reaction to bortezomib, can be ameliorated by subcutaneous administration, with no apparent loss in efficacy. 23 Carfilzomib (Kyprolis), a second-generation proteasome inhibitor approved in 2012 for RRMM, offers the advantage of reduced peripheral neuropathy and has demonstrated effectiveness in patients with relapse after bortezomib therapy. However, drug resistance has been noted, and, importantly, cardiovascular-related adverse events associated with carfilzomib, first observed in the initial trials 24 and recently confirmed by a meta-analysis, have raised particular concern. 25 Similar to bortezomib, carfilzomib is used intravenously and targets the CT-L beta-5 subunit; however, because of its epoxide ring functionality, it does so irreversibly. 26 In late 2015, ixazomib (Ninlaro; MLN9708), another boronic acidderived reversible beta-5 CT-L inhibitor, became the most recently approved agent in this class for use with lenalidomide and dexamethasone in MM patients who had received ! 1 previous therapy. 27 Ixazomib's oral availability and once-weekly dosing schedule offer a distinct advantage over previously approved proteasome inhibitors. Its toxicity profile is similar to that of bortezomib, although ixazomib appears to be associated with reduced incidence of peripheral neuropathy, possibly because of its greater selectivity for the CT-L subunit. Two newer proteasome inhibitors are now under clinical investigation for their antimyeloma activity (Table 2) . Marizomib (NPI-0052), obtained from a marine actinomycete, is a potent irreversible inhibitor of all 3 core enzyme activities of the 20S proteasome. A phase I study (ClinicalTrials.gov identifier, NCT02103335) reported marizomib's clinical activity (ORR, 53%; clinical benefit, 64%) by the intravenous route in combination with pomalidomide and dexamethasone in previously treated RRMM patients, with no evidence of hematologic toxicity or peripheral neuropathy. 28 Also, marizomib as a single agent has been the focus of completed phase I 29 and phase II (ClinicalTrials.gov identifier, NCT00461045) studies in the RRMM setting. Oprozomib (ONX-0912), an orally bioavailable CT-L irreversible proteasome inhibitor structurally related to carfilzomib, has been included in phase I/II MM trials, both as a single agent 30 and in various combination therapies ( Table 2 ). The most frequently encountered adverse effects noted in the oprozomib studies have been gastrointestinal with no reports of peripheral neuropathy. Recently, all work on a third investigational antimyeloma proteasome inhibitor, delanzomib (CEP-18770), was terminated because of a lack of efficacy. 31 Two new oral proteasome inhibitors, LC53-0110 and LC53-0151, which have demonstrated very high affinity for the chymotrypsin (beta-5) site, have shown remarkable potency in the low nM range in preclinical myeloma models. 32 Removal of ubiquitin tags occurs in the 19S proteasome RP caps before peptide cleavage. Three major types of deubiquitinases (DUBs) are found in mammalian 19S RPs: ubiquitin-specific peptidases (USPs), ubiquitin C-terminal hydrolases (UCHs), and a zinc metalloprotease. Upregulation of DUBs, particularly USPs, is associated with a poor prognosis in MM, possibly owing to stabilization of the anti-apoptotic Mcl-1, providing impetus for current research in this area. 33 VLX1570, which inhibits USP14 and, to a lesser extent, the UCH isozyme L5, was the focus of a nowsuspended (owing to safety concerns) phase I/II investigation with dexamethasone for RRMM (ClinicalTrials.gov identifier NCT02372240). P5091 and b-AP15 are 2 additional DUB inhibitors that have exhibited favorable preclinical activity in MM, although they have yet to be advanced to clinical trials. 34 Because proteasome degradation is a normal mechanism for disposal of cellular proteins, proteasome inhibition can produce a number of serious adverse effects, such as those noted previously. Efforts to obviate the loss of normal protein function have spurred research into possible targets upstream from proteasomal degradation. One such target is the ubiquitin-like proteins (ULPs), each of which has its own set of activating enzymes, analogous to the ubiquitin E1-E3 conjugating systems. Among these ULPs is NEDD8 (neural precursor cell expressed developmentally downregulated-8), an 81-amino acid protein sharing 60% sequence identity and 80% homology with ubiquitin. It has been estimated that w20% of proteins targeted for degradation by the UPS are ubiquitinated through the ULP pathway. A subtype of ubiquitin ligase known as cullin-RING (real interesting new gene) ligases or NEDD8-activating enzyme serves as the substrate for NEDD8, catalyzing attachment (neddylation) of NEDD8 to a cullin family member. 35 Two specific inhibitors of NEDD8-activating enzyme, pevonedistat (MLN4924) and TAS4464, have been of interest as possible therapeutic agents in MM. However, RRMM patients failed to respond in a phase I trial of single-agent pevonedistat (ClinicalTrials.gov identifier, NCT00722488) that also included lymphoma patients. 36 TAS4464 was the focus of a safety and efficacy trial in MM and lymphoma patients (ClinicalTrials.gov identifier, NCT02978235).
Heat Shock Proteins and UPR
In addition to the role played by proteasomes as regulators of the functional proteome, 2 other cellular networks serve a similar purpose-the heat shock proteins (HSPs) and the UPR, each of which has been shown to be dysregulated in myeloma cells. HSPs are a large group of highly conserved ATP-dependent molecular chaperones best known for their critical role in support of proper protein folding. However, mammalian HSPs, which are grouped according to their molecular weights in kDa-HSP100, HSP90, HSP70, HSP60, and HSP27-also are known to engage in a wide array of other specific functions that regulate protein homeostasis and promote cell survival. Ample evidence exists that links upregulation of HSPs with development of several different cancers, including MM. Moreover, activation of the heat shock response is believed to be a major mechanism by which myeloma cells develop resistance to bortezomib. 37 May 31, 2018) . HSF1 (heat shock transcription factor 1), an important regulator of the heat shock response in myeloma cells also has been proposed as a potential target for MM. Although a number of HSF1 inhibitors have been the subject of preclinical studies of MM, all have been lacking in specificity, and none has been advanced to clinical studies of patients. 39 The UPR is activated by the accumulation of misfolded proteins in the endoplasmic reticulum (ER), a state known as ER stress, which leads either to a restoration of protein homeostasis or, if the level of damage is excessive, to apoptosis. These pathways are mediated by 3 interrelated signaling mechanisms in which either PERK (protein kinase RNA-like endoplasmic reticulum kinase), IRE1a (inositol-requiring enzyme-1a), or ATF6a (activating transcription factor 6a) serves as the initiating sensor. Grp94, also known as Gp96 and HSP90b1, is an isoform of HSP90 that resides in the ER, where it functions as a key player in the UPR. Upregulation of Grp94 expression in different malignancies, including MM, has made this isoform an attractive target for antitumor drug design and development. Although none has progressed to human studies, 3 promising candidates in this field are PU-H54, PU-WS13, and PU-H39, purine-based derivatives that selectively attach to the ATP allosteric binding pocket.
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GSK2656157 and GSK2606414, both oral inhibitors of the PERK arm of the UPR, have demonstrated anti-MM activity, although neither has entered clinical trials for cancer treatment.
41,42

Epigenetic Approaches
Fundamentally, eukaryotic chromatin organization is based on the nucleosome, an octameric structure formed by 4 pairs of histones-H2A, H2B, H3, and H4-around which w146 DNA base pairs are wrapped. The accessibility of DNA to the transcriptional apparatus is determined in large measure by the compactness of this winding, with tight winding (heterochromatin) associated with gene silencing and more open conformations (euchromatin) favoring gene expression. Post-translational modifications (acetylation, methylation, phosphorylation, ubiquitination, and sumoylation) to histones play a key regulatory role in determining gene expression. These, together with DNA-base (mostly, cytosine) methylations, are collectively referred to as "epigenetics"-changes in gene activity not due to changes in nucleotide sequence. One of the most important of these modifications is acetylation of epsilon-amino groups of lysine residues located at N-termini of histone tails. Acetylated histones cause relaxation of DNAehistone interactions, enhancing DNA accessibility and transcriptional activation. In this context, agents that promote acetylation or deacetylation, via histone acetyltransferases or histone deacetylases, respectively, of these lysine residues have assumed an important place in drug research during the past 20 years.
HDAC Inhibitors
Histone deacetylases (HDACs) remove acetyl groups from lysine residues of, not only core histones, 43 but also of nonhistone proteins, such as tubulin, p53, NF-kB, STAT3, and HSP90, leading to faulty gene expression and aberrant cellular signaling. 44 The classic HDACs are divided into 4 classes (I, IIA, IIB, and IV) differing in sequence homology, enzymatic activity, cellular localization, and substrate specificity. 45 The members of each class are as follows: class I (confined to the nucleus), HDAC1-3 and HDAC8; class IIA (distributed between the nucleus and cytoplasm), HDAC7 and HDAC9; class IIB (found primarily in the cytoplasm), HDAC6 and HDAC10; and class IV (found in the nucleus and cytoplasm), HDAC11. The catalytic activity of each of these 4 classes is dependent on Zn þ2 . In contrast, HDAC class III members, known as sirtuins 1 to 7 in mammals and sirtuin 2 in yeast, are dependent on NAD þ for activity. HDAC overexpression has been reported in several solid tumor types and in hematologic cancers and often correlates with a poor prognosis. 46 However, exceptions exist, such as in breast cancer and some leukemias, for which the prognosis is enhanced with elevated HDAC levels. In the case of MM, in particular, HDAC1 overexpression has been associated with a poor prognosis and with resistance to bortezomib. Tandon et al 47 recently reviewed the present role of HDAC inhibitors in myeloma treatment. The efficacy of using HDAC inhibitors as potential treatments for MM was demonstrated > 1 decade ago by preclinical studies using vorinostat alone and combined with bortezomib. 48 Recently, Imai et al 49 reviewed the mechanisms of action of HDAC inhibitors in several hematologic cancers, including MM. A key aspect of the mechanism is the aggregation of misfolded and unfolded ubiquitinated proteins into perinuclear aggresomes, a process that is dependent on the microtubule network, the motor protein dynein, HDAC6, and the UPR. 50 Aggresomes eventually are removed by autophagic clearance. HDAC inhibition, especially combined with proteasome inhibition, results in synergistic blockade of disposal of several proapoptotic proteins through the UPR, altering the balance between pro-and antiapoptotic proteins to favor cytotoxicity. Although HDAC inhibitors have demonstrated anti-myeloma activity as single agents in preclinical studies, their use in RRMM clinical trials generally has been disappointing, [51] [52] [53] prompting their evaluation in combination with other drugs, mostly proteasome inhibitors. The pan-HDAC inhibitors panobinostat and vorinostat, which target > 1 class of HDAC, have been the most widely studied in this context. The active clinical trials of investigational HDAC inhibitors under consideration as potential MM drugs are listed in Table 3 .
Pan-HDAC Inhibitors
Panobinostat (Farydak; LBH589) is an orally active nonselective HDAC inhibitor that thus far is the only member of this class approved for use in MM. FDA approval was granted in February 2015 for the treatment of RRMM in combination with bortezomib and dexamethasone in patients who have received ! 2 previous therapies, including bortezomib and an immunomodulatory agent. 54 Approval was predicated on the results of the multicenter randomized double-blind phase III PANORAMA-1 (panobinostat oral in multiple myeloma) trial (n ¼ 768; ClinicalTrials.gov identifier, NCT01023308). In that trial, patients treated with panobinostat plus bortezomib plus dexamethasone showed a median progression-free survival (PFS) benefit of 7.8 months compared with the PFS for those who had received ! 2 previous treatments that included both bortezomib and an immunomodulator, a patient population known to have poorer prognosis and limited treatment options. However, the prescribing information 55 for panobinostat includes a warning regarding the drug's increased risk of potentially fatal cardiac toxicity (ischemia, arrhythmias, ST-segment depression, and T-wave abnormalities) and severe diarrhea, as revealed in the PANORAMA-1 study. Vorinostat (suberoylanilide hydroxamic acid; SAHA; MK-0683) and belinostat (PXD101), another pan-HDAC inhibitor, have been approved by the FDA for T-cell lymphomas. However, myeloma-based clinical trials (ClinicalTrials.gov identifiers, NCT00773747, NCT00431340, and NCT00131261) of both agents failed to yield clear evidence of a statistically significant therapeutic benefit. 56, 57 Thus, they are no longer considered viable candidates for further work in MM. 56, 57 Abexinostat (PCI-24781), quisinostat (JNJ-26481585), AR-42, CUDC-907, and gavinostat (ITF2357) all represent orally active inhibitors of both class I and class II HDACs. Abexinostat has been included in 2 completed phase I trials for MM (ClinicalTrials.gov identifiers, NCT01149668 and NCT00562224) and for leukemias and lymphomas, although no data concerning the outcomes have yet been reported. Quisinostat has been the subject of a phase I dose escalation study in combination with bortezomib and dexamethasone for patients with relapsed MM (ClinicalTrials.gov identifier, NCT01464112). An ORR of 88.2% (15 of 17) was achieved in that study, in which the most common adverse events noted were thrombocytopenia, asthenia, and diarrhea. Clinically significant cardiac toxicity in the form of T-wave inversion and QTc prolongation, attributed to quisinostat, was noted in 1 study patient. 58 AR-42 has demonstrated preclinical activity against MM, where its primary effect has been ascribed to downregulation of CD44. The overexpression of CD44 is believed to be a contributing factor to lenalidomide and dexamethasone resistance in MM cells. AR-42 has been the subject of 2 phase I studies that included MM patients. In 1 now-suspended study (ClinicalTrials.gov identifier, NCT02569320), it was reported that AR-42 failed to elicit any confirmed partial responses in 13 relapsed MM patients, although 3 marginal responses were noted. 59 The second study (ClinicalTrials.gov identifier, NCT01129193), which investigated AR-42 in 27 patients with advanced or relapsed MM and CLL and patients with various types of lymphoma showed the compound to be safe and tolerable. 60 CUDC-907 is not only an inhibitor of HDAC classes I and II, but also of phosphatidyl-inositol 3-kinase (PI3K; class I alpha, beta, and gamma). Its structural design was based on the incorporation of pharmacophoric features common to both groups of inhibitors as a method to provide therapeutic advantages through disruption of 2 signaling networks frequently upregulated in many hematologic cancers. An open-label dose-escalation phase I trial of CUDC-907 in lymphoma and MM patients with relapsed or refractory disease (ClinicalTrials.gov identifier, NCT01742988) has established the compound's suitability for a subsequent phase II study. 61 
Class-and/or Isotype-selective HDAC Inhibitors
Ricolinostat (ACY-1215) and citarinostat (ACY-241) are second generation orally active HDAC inhibitors that selectively inhibit HDAC6, offering the possibility of enhanced potency in combination with proteasome inhibitors and reduced off-target toxicity. 62, 63 Clinical trials of both drugs in MM are ongoing (Table 3) . 4SC-202 currently is under development as an oral class I HDAC inhibitor, selective for HDACs 1 to 3 and as an inhibitor of histone lysine-specific demethylase. 64 This drug has been studied in (EDO-S101), mentioned earlier as a fusion product linking vorinostat with the DNA-damaging alkylating agent bendamustine, selectively inhibits HDACs 1, 2, and 6, blocks HDAC-associated DNA repair, and has demonstrated antitumor activity in both cell culture and xenograph models. 7 
Bromodomain Inhibitors
Sites of lysine acetylation on histones also serve to recruit transcription factors, such as the RNA polymerase II complex, that contain a bromodomain (BRD) specifically capable of recognizing ("reading") these acetylation sites. A total of 46 BRD-containing proteins, with 61 distinct BRDs, divided into 8 major families, are known to occur in the human proteome. 67 A subset of BRDcontaining proteins, the BRD and extraterminal (BET) family, is characterized by the presence of 2 BRDs in their N-terminal regions. Major members of the BET family include BRD2, BRD3, BRD4, and the testis-specific BRDT. In particular, the BRD4 BRD is known to bind to so-called superenhancer regions of DNA, promoting expression of key oncogenes, 68 such as c-MYC, which is activated in > 60% of MM patients. 69 Several small molecule inhibitors of the proteineprotein interaction between BRDcontaining proteins and histones have been developed for potential therapeutic applications, primarily for cancer, but also for cardiovascular disease and diabetes mellitus. 70 Two orally bioavailable BET inhibitors have demonstrated anti-myeloma activity in preclinical models and currently are in phase I trials of advanced MM (Table 3) : CPI-0610 71 and RO6870810. No results have yet been reported from either of these trials.
Apoptosis Inducers: Bcl-2, IAP, and
Mcl-1 Inhibitors
One of the hallmarks of cancer cells is their ability to evade apoptosis through 1 of 2 basic pathways-external and internalboth of which cause upregulation of mediators promoting malignant cell survival. In the external pathway, extracellular ligands bind to cell-surface receptors belonging to the tumor necrosis factor superfamily. The internal counterpart is regulated by members of the Bcl-2 (B-cell lymphoma-2) family of proteins, which can have either pro-death or pro-survival properties. The internally generated members work by heterodimerizing with, and thus neutralizing, those members with the opposite attributes. Especially noteworthy in this regard are the conserved Bcl-2 homology (BH) death domains (numbered BH1-4) that occur in both pro-and antiapoptotic members. Bax and Bak are among the major proapoptotic effectors, so-called BH3-only members, and Bcl-2 itself (the founding member of the class), BclX L (B-cell lymphoma-extra large), and Mcl-1 (myeloid cell leukemia-1) are antiapoptotic proteins that possess other BH domains, in addition to BH3. Recently, BH3-selective mimetics have received attention for their ability to interfere with proteineprotein interactions between these opposing classes of proteins, antagonizing the effects of the antiapoptotic counterparts and thereby inducing cell death. 72 Dysregulation of the apoptotic pathway in MM has been the focus of several studies in recent years with the aim of identifying novel therapeutic targets. For example, overexpression of both Mcl-1 and Bcl-2 has been implicated in mediating survival in a subset of myeloma cells. 73 Venetoclax (Venclexta; ABT-199) is an orally bioavailable small molecule Bcl-2 inhibitor, acting as a BH3 mimetic, that was approved in April 2016 by the FDA for use in CLL patients exhibiting a 17p chromosomal deletion and associated loss of the tumor suppressor TP53. Venetoclax has been found to produce apoptosis in human myeloma cell lines, including primary samples from MM patients, especially those harboring the t (11;14) translocation. 74 This is particularly noteworthy because MM patients with this genetic identifier are known to respond poorly to standard anti-myeloma therapies. 75 Significantly, a subsequent phase I trial (ClinicalTrials.gov identifier, NCT01794520) of venetoclax monotherapy in heavily pretreated RRMM patients, receiving 1200 mg/d, found that 12 of the 14 patients (of a total of 166 evaluable patients) who exhibited an objective response had the t(11;14) myeloma cell subtype. 76 A follow-up phase Ib trial (ClinicalTrials.gov identifier, NCT01794507) of 66 RRMM subjects combining venetoclax with bortezomib and dexamethasone found the combination to be well-tolerated, although no major difference in ORR attributable to t(11;14) biomarker status was observed (78% with the marker and 65% without). 77 This similarity in responses between these 2 groups was ascribed to bortezomib's indirect role as a stabilizer of the proapoptotic protein NOXA, which is known to neutralize Mcl-1, 78 a promoter of myeloma cell survival, 79 and to dexamethasone's capacity to sensitize myeloma cells to venetoclax. 80 The 8 active trials evaluating venetoclax for its potential in RRMM are listed in Table 4 . Especially noteworthy are 2 phase III studies, in 1 of which (begun in 2016) the combination of venetoclax, bortezomib, and dexamethasone is being assessed (ClinicalTrials.gov identifier, NCT02755597). The other, initiated in May 2018, is a multicenter trial (ClinicalTrials.gov identifier, NCT03539744) to evaluate venetoclax as a prognostic indicator specifically in t(11;14)-positive myeloma patients. The results of these trials should help guide future development of this agent in RRMM and other compounds working by a similar mechanism, especially in the subset of patients bearing the t(11;14) chromosomal translocation.
Another BH3 mimetic, R-(-)-gossypol (AT-101), 81 a naturally occurring polyphenol found in the cotton plant, has been studied against a number of cancers and is currently being investigated in a phase I/II study with lenalidomide and dexamethasone for relapsed MM (ClinicalTrials.gov identifier, NCT02697344). Also, MM patients have been included in a study of S55746/BCL201 (ClinicalTrials.gov identifier, NCT02920697), described as an oral Bcl-2 inhibitor with acceptable tolerability and safety features in lymphoma patients. 82 The identification of upregulated Mcl-1 as a determinant of myeloma cell survival, 79 as noted, has prompted studies of Mcl-1 inhibitors for their activity in MM. Three such inhibitors recently have entered clinical trials for RRMM and other cancers: AZD5991 (ClinicalTrials.gov identifier, NCT03218683), 83 AMG 176 (ClinicalTrials.gov identifier, NCT02675452), and MIK 665 (ClinicalTrials.gov identifier, NCT02992483).
The proteolytic aspects of apoptosis are performed by a series of endoproteases known as caspases (cysteine-dependent aspartatedirected proteases), so-named because their mechanism includes nucleophilic attack by an active-site cysteine SH (sulfhydryl) group on the C-terminal side of an aspartate-containing peptide linkage. In mammals, caspase-3, -6, -7, -8, and -9 are involved in apoptosis, categorized according to whether they act as initiators (caspase-8 and -9) or executioners (caspase-3, -6, and -7) of the process. 84 Caspase-8 is activated in the extrinsic pathway; in the intrinsic pathway, release of cytochrome c from mitochondria causes activation of caspase-9, which, in turn, activates the executioner caspase-3, -6, and -7. The release and activation of caspases are controlled by members of the IAP (inhibitors of apoptosis) family. The 3 best studied are the 2 cellular IAPs (cIAP1 and cIAP2) and XIAP (X-linked inhibitor of apoptosis), which are overexpressed in many cancers, making them prime targets for new anti-myeloma drug design and development. 85 Second mitochondria-derived activator of capsase (Smac; also known as Diablo), which binds to IAPs, enabling caspases to initiate apoptosis, has been validated as a potential therapeutic target for cancer. The Smac mimetic LCL161 currently is the subject of a phase II trial (ClinicalTrials.gov identifier, NCT01955434) with cyclophosphamide in RRMM. An initial report showed 5 patients receiving the combination had a median PFS of 10 months. 85 It was speculated, based on in vivo studies in mice, that the potent antitumor activity of LCL161 might be the result of an apoptosis-independent mechanism, whereby upregulation of interferon signaling and consequent activation of macrophages and dendritic cells caused phagocytosis of tumor cells.
Additional Targets
Kinesin Spindle Protein Inhibitors
Kinesin spindle proteins (KSPs or Eg5), members of the kinesin superfamily of microtubule motor proteins, play a major role in mitosis. Relying on ATP hydrolysis to provide the mechanical energy required for centrosome separation and bipolar spindle assembly during cell division, KSP binds to microtubules and enables them to slide apart during sister chromatid segregation. Inhibition of KSP results in formation of a monopolar (instead of the normal bipolar) spindle, mitotic cell cycle arrest at the spindle checkpoint, and subsequent apoptosis. MM cell lines whose proliferation is sustained by the antiapoptotic Bcl-2 family member Mcl-1 (see the previous section, Apoptosis Inducers: Bcl-2, IAP, and Mcl-1 Inhibitors), are especially sensitive to KSP inhibitor-induced apoptosis, leading to a proposal that Mcl-1 status in hematologic malignancies, including myeloma patients, might be a useful predictor of the response to KSP inhibitors. 86 Because KSP inhibitors do not act directly on tubulin and are active only in rapidly proliferating cells, together with the observation that tubulin is involved in cellular processes other than mitosis, might confer on this group of drugs the advantage of avoiding the peripheral neuropathy associated with direct-acting tubulin inhibitors, such as the taxanes and Vinca compounds.
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Although 2 other KSP inhibitors (ARQ621 and AZD4877) have been included in clinical studies for hematologic malignancies, thus far, filanesib (ARRY-520) is the only KSP inhibitor to be advanced to patient studies specifically for MM. Preclinical work showed that filanesib possessed good in vivo activity against a number of myeloma cell lines, both alone and combined with immunomodulating agents. 88 In a phase I trial (ClinicalTrials.gov identifier, NCT01248923) with filanesib in RRMM, Chari et al 89 reported an ORR of 42% in a well-tolerated regimen with bortezomib. Filanesib has been included in 2 phase II studies. In 1, preliminary results from a trial of carfilzomib with and without filanesib (ClinicalTrials.gov identifier, NCT01989325) showed an ORR of 10% in the carfilzomib cohort (n ¼ 20) compared with 30% in the arm that included filanesib (n ¼ 30). 90 Another study (ClinicalTrials.gov identifier, NCT02092922; AfFirm [a phase 2 trial of filanesib in relapsed/refractory multiple myeloma]) showed that addition of dexamethasone to a filanesib regimen improved the ORR (28% vs. 15%) in patients with MM refractory to bortezomib and lenalidomide. 91 The most common adverse effects attributed to filanesib in these studies were thrombocytopenia, anemia, neutropenia, and fatigue.
Poly(ADP-ribose) Polymerase Inhibitors
The post-translational addition of ! 1 ADP-ribose units to a variety of nuclear proteins is catalyzed by poly(ADP-ribose) polymerase (PARP), using NAD þ as the source of ADP-ribosyl units and ATP to effect regeneration of the consumed NAD þ . Although PARP targets include a variety of substrates, such as histones and transcription factors, interest in PARP inhibitors as therapeutic agents has centered around the enzyme's role in repairing DNA single-and double-strand breaks. Activation of PARP by single-or double-strand breaks causes PARPylation and consequent recruitment to the damage site of several proteins involved in repairing the break. 92 The human PARP family is thought to be composed of as many as 17 members, 2 of which (PARP-1 and PARP-2) have been the focus of drug development. Olaparib (Lynparza), an oral PARP-1 and PARP-2 inhibitor, was approved by the FDA in 2014 as treatment for germline BRCAmutated ovarian cancer (subsequently extended to BRCA-mutated HER2 À metastatic breast cancer). This marked the first example of the successful development of a drug based on the concept of synthetic lethality, 93 which was first advanced 2 decades ago by
Hartwell et al. 94 This hypothesis proposes that synthetic lethality between 2 genes occurs when loss of function of both genes results in cell death but that loss of either individual gene is compatible with life. A search of the ClinicalTrials.gov website revealed that veliparib (ABT-888) is the first PARP inhibitor to be tested against MM. The phase I trial (ClinicalTrials.gov identifier, NCT01495351) of oral veliparib and bortezomib for heavily pretreated RRMM patients was predicated on preclinical studies showing synergy between PARP and proteasome inhibitors in which the latter induced a "BRCAness" state in myeloma cells that sensitized them to the former. 95 The initial results indicated that the combination is well-tolerated with evidence of significant antimyeloma activity reported. 96 However, a 2017 report (available at: https://news.abbvie.com/news/abbvie-announces-topline-resultsfrom-two-phase-3-studies-investigating-veliparib-in-combinationwith-chemotherapy-for-treatment-patients-with-advanced-or-metastatic-squamous-non-small-cell-lung-cancer-and-early-stage-triplenegative-breast-cancer.htm; accessed May 31, 2018) from the drug's sponsor (AbbVie) of failure to meet the primary endpoints in 2 phase III trials of veliparib in nonesmall-cell lung cancer and triple-negative breast cancer has cast a shadow over the future viability of this PARP inhibitor for these and other cancers, including MM.
MDM2 Inhibitors
The tumor suppressor protein p53 has been extensively studied for its role in responses to a number of cellular stresses, such as DNA damage, hypoxia, telomere erosion, oxidative stress, and oncogene activation. 97 The prominent role played by p53 in cancer has been underscored by the frequently reported statement that TP53 mutations are the most frequently found genetic aberrations in all cancers, being observed in > 50% of human malignancies. 98 The actions of p53 in the cell are very complex and appear to be most important in transcriptional activation or repression of hundreds of the genes required for normal cellular homeostasis. In addition, p53 is known to play a central role in several nontranscriptional activities. One of the earliest uncovered roles for p53 was its ability to induce apoptosis in DNA-damaged cells by blocking the cell cycle at the G 1 /S and G 2 /M checkpoint interfaces.
The activity of p53 is regulated by a number of effectors, the best studied of which is MDM2 (murine double minute 2), a zinc-finger protein, which controls p53 activity through 2 major mechanisms. One mechanism involves binding of MDM2 to the p53 N-terminal domain to block the latter's capacity to effect transcription. The second mechanism is accounted for by the ability of MDM2 to promote ubiquitination of p53, thus marking it for proteasomal degradation. MDM2 is upregulated in several types of cancer, including MM, rendering MDM2 a prime target for new drug development.
99 MDM2 inhibitors are small molecules that work by blocking the proteineprotein interaction involved in the wild-type p53eMDM2 interaction. 97 Three oral agents classed as MDM2
inhibitors now are in clinical trials for MM (Table 5) : idasanutlin (RG7388, RO 5503781), DS-3032b, and AMG-232. No results from these trials have been reported yet.
Exportin Inhibitors
Transport of proteins and RNA into and out of the nucleus is controlled by the nuclear pore complex (NPC), a large cylindrical protein complex (100-150 nm in diameter and 50-70 nm in thickness; 125,000 kDa), composed of ! 30 different proteins (nucleoporins) organized into several subcomplexes and forming an aqueous channel that fuses the external and internal nuclear membranes. 100 Transport through the NPC is mediated by proteins belonging to the karyopherin-b superfamily, which has 2 major functional types-importins and exportins. The importins bind to specific signal sequences (nuclear localizing sequences [NLS]) on their respective cargo molecules in the cytoplasm for transport into the nucleus. The exportins accomplish the opposite process, transporting proteins and RNA out of the nucleus through the NPC, likewise mediated by recognition of cargo NLS tag sequences. Regulation of the transport process is governed by Ran, a Rasrelated GTPase. 101 Exportins bind RanGTP and export cargo in the nucleus. Hydrolysis to RanGDP by the GTPase activating protein RanGAP provides the energy necessary for transport out to the cytoplasm. In contrast, importins release their cargo inside the nucleus on binding to RanGTP. Exportin-1 (XPO1), also known as CRM1 (chromosome region maintenance 1), 1 of the best characterized exportins, is responsible for transporting a broad range of proteins, including cell cycle regulators, tumor suppressor proteins, and transcription factors, from the nucleus into the cytoplasm. 102 Overexpression of XPO1 has been found in several types of cancer, including pancreatic cancer, renal cell carcinoma, glioma, osteosarcoma, MCL, acute and chronic leukemia, and MM and is associated with a poor prognosis. 103 Drug research in this arena has focused primarily on orally bioavailable small molecule irreversible covalent XPO1 inhibitors, collectively referred to as selective inhibitors of nuclear export (SINE). These compounds were designed in silico to react covalently with cysteine 528 at the NES hydrophobic binding site of human XPO1, thus blocking the interaction of the exportin with its cargo. Moreover, XPO1 has been identified in genome-wide studies as a valid target for drug design and development in MM. 103 Inhibiting translocation of key tumor suppressor proteins into the cytoplasm and thus promoting their nuclear retention is believed to be a major factor favoring apoptosis of malignant cells subjected to XPO1 inhibition. Selinexor (KPT-330), given orally, is the leading drug candidate in the SINE field for treatment of several malignancies, including MM. 104 Preclinical studies demonstrating synergy of selinexor with proteasome inhibitors, as well as immunomodulators, and dexamethasone provided a basis for several active trials of this agent in MM (Table 5 Table 5 .
Kinase Inhibitors
During the past 2 decades, kinase-activated signaling pathways have been of substantial interest as targets for discovery of new therapeutic classes to treat several cancers, including MM. 108 However, although some small molecule kinase blockers, especially oral tyrosine kinase inhibitors, such as imatinib, dasatinib, nilotinib, and ibrutinib, have had a major effect on the treatment of some hematologic malignancies, other tyrosine kinase inhibitors such as linsitinib, masitinib, cabozantinib, tivantinib, nintedanib, pazopanib, sorafenib, and vatalanib thus far have shown little promise in myeloma-based trials.
A representative list of the MM clinical trials initiated in recent years that included kinase inhibitors is presented in Table 6 . Lately, attention has turned to the search for inhibitors of the receptor tyrosine kinase fibroblast growth factor receptor 3, 1 of the most significantly mutated genes in MM, found in w15% of MM patients, associated with a t(4;14) translocation and linked to chemotherapeutic resistance and a poor prognosis. 109 The leading candidate in this area is erdafitinib (JNJ-42756493), an oral panfibroblast growth factor receptor inhibitor, 110 now recruiting for a phase II study in combination with dexamethasone for RRMM patients (ClinicalTrials.gov identifier, NCT02952573). In a related development, a phase I study (ClinicalTrials.gov identifier, NCT03143985) of vactosertib (TEW-7197), an oral inhibitor of the serine/threonine kinase transforming growth factor receptor, in combination with pomalidomide, was initiated in 2017. Much of the kinase-related work in MM has focused on the central role played by Ras, which is known to be among the most frequently mutated oncogenes (eg, HRAS, NRAS, and KRAS ) in human cancers, including MM, in which it exhibits a prevalence of w42%. 111 In MM, a key manifestation of Ras mutations is increased activation of the Raf/Mek/extracellular signal-regulated kinase (Erk) downstream pathway. In addition to the Mek-Erk pathway, the PI3K-Akt (protein kinase B)-mTOR (mechanistic target of rapamycin) route, also operating downstream of Ras, has come under intense scrutiny in the search for druggable targets for RRMM. For the most part, this has resulted in trials that have combined agents blocking both Mek and PI3K signaling pathways. For example, a phase I trial (ClinicalTrials.gov identifier, NCT01476137) combining trametinib with the Akt blocker afuresertib (GSK2110183) was reported to be poorly tolerated at the doses studied. 114 Another Akt inhibitor uprosertib (GSK2141795) has been included with trametinib in an ongoing phase II trial (ClinicalTrials.gov identifier, NCT01951495) in which a modest ORR of 27% was reported. 115 In addition, the oral PI3K
inhibitor alpelisib (BYL719) and the Pim inhibitor LGH447 currently are under study in a combined regimen (ClinicalTrials.gov identifier, NCT02144038). ONC 201, 116 described as a broadspectrum antitumor drug with efficacy against both solid tumors and hematologic malignancies by blocking both Akt and Erk, has been included in 2 early trials (ClinicalTrials.gov identifiers, NCT02863991 and NCT02609230) that include MM patients, although preliminary data have not yet been reported. mTOR inhibitors, such as everolimus and temsirolimus, generally have fared poorly in MM trials as single agents, possibly owing to their capacity to cause feedback activation of Akt. 117 The National Cancer Institute database currently lists 2 active phase I/II trials that include MM patients in which everolimus, combined with either panobinostat (ClinicalTrials.gov identifier, NCT00918333) or the Raf kinase inhibitor sorafenib (ClinicalTrials.gov identifier, NCT00474929), is under study in hematologic malignancies. One target that has drawn considerable interest among the kinases is the Bruton tyrosine kinase (BTK), a nonreceptor kinase known to play a critical role in B-cell development and whose expression in myeloma cells has been reported as robust. 118 The oral irreversible BTK inhibitor ibrutinib, which has been approved by the FDA for MCL, CLL (including 17p deletion), Waldenström macroglobulinemia, marginal zone lymphoma, and chronic graftversus-host disease, currently is the focus of 5 trials for RRMM (Table 6 ). One phase II study of ibrutinib, in a regimen that also included carfilzomib and dexamethasone, produced an ORR of 72%, which included 2 complete responses and 8 very good partial responses, in 72 RRMM patients. 119 Acalabrutinib, another oral BTK inhibitor, approved by the FDA in 2017 for MCL, also has attracted interest for possible application in RRMM (ClinicalTrials.gov identifier, NCT02211014). Strategies focused on cyclin-dependent kinases (CDKs) as anticancer targets represent another important avenue in the search for new drugs to treat malignancies. CDKs act in concert with cyclins, their regulatory partner proteins, which are subject to fluctuating expression at defined points in the cell cycle. Complexes formed between specific CDKs and their associated cyclins at certain stages of the cycle assist in controlling progression through the cycle. One of the most important of the CDKecyclin interactions, that which occurs between CDKs 4 and 6 and cyclin D to control the cycle's G 1 /S transition, frequently is dysregulated in cancers. Although inhibitors of CDK4/6, such as palbociclib, ribociclib, and abemaciclib, recently have made substantial inroads into the therapy of estrogen receptor-positive breast cancer, the effect of this drug class in RRMM appears at this point to be minimal, as evidenced by the result of a phase I/II study (ClinicalTrials.gov identifier, NCT00555906) of palbociclib plus bortezomib and dexamethasone, in which an ORR of only 20% was attained. 120 A phase I trial (ClinicalTrials.gov identifier, NCT01711528) of dinaciclib, a blocker of CDK5 (an atypical CDK neither associated with cyclins nor involved in cycle regulation), with bortezomib and dexamethasone has been completed but no study results have been reported.
Summary and Future Prospects
Improved MM patient survival is 1 of the most remarkable success stories in cancer treatment in the early years of the 21st century. This has been achieved, at least in part, as a result of insight gained into the control mechanisms that maintain normal homeostasis and drive transformation of normal plasma cells into their neoplastic counterparts. During the past decade, much of the attention in the search for innovative treatment options for MM has been toward immunotherapeutic approaches, as witness the regulatory approval in 2015 of 2 monoclonal antibodies, daratumumab and elotuzumab. Additionally, work on a number of related immunologic-based targeting strategies, including those predicated on the chimeric antigen receptor T-cell concept, continues apace.
Although macromolecular-based therapies have gained increasing importance in MM therapy, small molecules with molecular weights of < 900 kDa continue to retain a position of prominence as valued components in the treatment of MM. This has been made possible by advances in understanding the roles played by proteasomes, epigenetics, genetic aberrations, and apoptotic processes to initiate and/or maintain the malignant state. Together, these discoveries have enabled the identification of new therapeutic targets that affect the disease, along with the development of computer-based methods to design novel molecules aimed at affecting those targets. Thus, proteasome inhibitors such as bortezomib, carfilzomib, and ixazomib and the HDAC blocker panobinostat have taken their place in the armamentarium of clinically beneficial anti-myeloma drugs. Moreover, a better understanding of the molecular mechanism underlying the favorable actions of IMiDs (thalidomide, lenalidomide, and pomalidomide) in MM has yielded a new strategy, cereblon modulation, for identifying innovative targets for new drug design and development in this class that formerly had been considered undruggable. 17 Several of the agents described in the present review signal that the advent of a new generation of oral agents to treat MM might be on the horizon. A clear example of this is the alkylating agent bendamustine, which has been licensed for myeloma therapy by the European Medicines Agency since 2010, and in recent years has received much attention in the United States, as evidenced by the 34 ongoing myeloma-based phase I and II trials of the drug. Melflufen, another alkylating agent, recently entered the phase III OCEAN trial for patients with lenalidomide-refractory MM.
Another agent that has exhibited potential is venetoclax, which has been approved by the FDA for CLL (17p deletion). This BH3 mimetic that inhibits Bcl-2, in combination with bortezomib and dexamethasone, currently is in a phase III myeloma-specific trial (ClinicalTrials.gov identifier, NCT02755597). Most significantly, the results from a recent study 76 demonstrating the effectiveness of oral venetoclax as a single agent in MM patients with the t (11;14) translocation has led to a recently announced phase III trial (ClinicalTrials.gov identifier, NCT03539744) of the drug in t(11;14)-positive RRMM patients. The results obtained in the present study might be especially impactful, because MM patients with this chromosomal aberration have been shown to exhibit poorer outcomes compared with standard-risk myeloma patients. 75 Two other oral agents that have attracted clinical scrutiny for MM are selinexor and its second-generation relative eltanexor. The former entered a phase III study (the BOSTON trial [bortezomib, selinexor, and dexamethasone in patients with multiple myeloma]) in 2017. The latter might prove very interesting owing to its improved tolerability, enabling more frequent dosing. Both selinexor and eltanexor are members of the SINE group of drugs that block exportin (XPO1). BRD inhibitors are another important emerging area for the development of new drugs for MM, as manifested by the two orally active members of this class, CPI-0610 and RO6870810, which have entered phase I studies for MM in recent years. Although targeted therapy with inhibitors of tyrosine kinase and related phosphorylating enzymes have had a considerable effect on chemotherapy of certain hematologic and other cancers in recent years, the therapeutic benefits of kinase inhibitors have yet to be realized for MM. The results of studies with inhibitors of BTK and other kinases (Table 6 ) might yet prove favorable to MM as innovative molecular design strategies, such as blockade of critical upstream kinase-activating proteineprotein interactions, are instituted in the kinase inhibitor field.
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Conclusion
As noted in the present review, target-guided molecular design, based on extensive research into the abnormalities underlying plasma cell transformation, has borne much fruit during the past 2 decades, leading to the introduction of several anti-myeloma drugs classed as small molecules. The demonstrated ability of these agents to complement autologous stem cell transplantation and the newer immunologic modalities to extend disease-free survival, whether as initial therapy 121 or for relapsed and/or refractory disease, 2 has been remarkable, although
the pathway forward appears no less arduous, because the development of resistance is bound to remain a substantial challenge. If the past 2 decades have been any harbinger, the years ahead hold great promise for the development of novel therapeutic options with improved oral efficacy and potential to not only extend PFS but also to improve the quality of life for patients with this unrelenting disease.
